ERBB2 and breast cancer: The combined mutational hotspots in members of the mitogen-activated protein kinase (MAPK) signaling cascades are frequently present in the HER2+ and triple-negative metastatic BC, which include CDH1 mutations, FOXA1 mutations [20] and ESR1 mutations [21].